On December 10, 2025, a thirteen-person expert panel convened by the FDA voted unanimously to expand testosterone access. Remove the prostate cancer warning. Deschedule from Schedule III. Broaden approved indications to include age-related low testosterone. Align labeling with the TRAVERSE safety findings.
Commissioner Makary drew an explicit parallel to the estrogen HRT black box removal the month before. The door was open.
That same month, a multilingual content analysis published in the Journal of Clinical Endocrinology & Metabolism found that 9.9% of online testosterone providers offered treatment to men whose testosterone was already normal. That 37.6% promoted "andropause" as a distinct medical diagnosis. That 4.7% accepted finger-prick self-tests as sufficient for a hormonal diagnosis whose measurement is the least reliable in endocrinology.
The same twelve months that produced the strongest evidence for expanded access also produced the strongest evidence against the way it's being expanded.
This is not a contradiction. It's two crises colliding.
The Access Crisis Is Real
The case for lowering barriers to testosterone treatment is genuine. Opioid-induced hypogonadism affects 21-86% of men on chronic opioids. Fewer than 10% are ever diagnosed. The veteran triad — PTSD, blast TBI, sleep fragmentation — gives 34% of VA patients low testosterone. Compliance with screening protocols at the Minneapolis VA was 0%.
The knowledge gap is structural. A 2022 secret-shopper study showed that only 1 in 7 mainstream providers asked about cardiovascular risk before prescribing testosterone. But the same study revealed something else: mainstream medicine isn't asking the right questions either. The access crisis isn't only about supply — it's about competence across the entire system.
Schedule III classification creates real friction. Every prescription requires DEA registration, triplicate forms, and prescription monitoring. California's AB-82, effective January 1, 2026, went the opposite direction — removing testosterone from its prescription monitoring database entirely. But descheduling at the federal level requires Congressional action (the Anabolic Steroids Control Act of 1990 placed testosterone on Schedule III by statute, not by FDA regulation), and as of March 2026, no bill has moved.
The Endocrine Society's submission to the FDA comment period (February 6, 2026) reveals the professional ambivalence: they called for 10- to 20-year follow-up studies before major label changes, even while acknowledging that TRAVERSE and four subsequent meta-analyses provide "reassurance" on cardiovascular safety. They did not explicitly endorse descheduling. The organization that writes the guidelines is more cautious than the panel that advises the FDA.
The Gold Rush
Into this vacuum stepped an industry.
A STAT News investigation (November 2025) identified 223 online testosterone clinics operating in 2023, with 325 new clinics opening since early 2024. The total is now likely in the thousands. No unified registry exists. Injectable testosterone cypionate prescriptions doubled between 2019 and 2025. Total testosterone prescriptions rose from 7.3 million to over 11 million annually.
The marketing language writes itself. "Enhanced Energy and Stamina." "Cognitive Clarity and Mood Stability." "Explosive Drive." "Muscular Definition." A KFF Health News/CBS investigation (March 2024) documented the playbook: Male Excel and Hone Health specifically target military veterans with promises the evidence does not support. The depression paradox shows that testosterone modulates dopaminergic motivation, not serotonergic mood. The cardiovascular paradox shows that the relationship between testosterone and heart health is U-shaped, not linear. None of this complexity survives translation into a subscription landing page.
The platforms vary, but the business model is consistent. Hims launched its testosterone platform in September 2025 with exclusive access to Kyzatrex (oral testosterone, Marius Pharmaceuticals), compounded enclomiphene, and an enclomiphene-tadalafil combination — claiming a "96% success rate" in restoring testosterone levels. Starting price: $99/month. Hone Health: $149/month subscription, BBB complaints from patients billed despite not receiving treatment. AlphaMD: $129/month — and among the "ancillary medications" listed alongside testosterone cypionate: oxandrolone and nandrolone, Schedule III anabolic steroids offered with no apparent additional clinical justification.
The pricing inversion is striking. Dubin and colleagues (Journal of Sexual Medicine, 2022) found that 12 months of injectable testosterone costs $1,586–$4,200 through DTC platforms versus $134–$1,333 through traditional tertiary medical centers. The initial DTC evaluation is cheaper. Everything after that is exponentially more expensive. The KFF investigation quantified the extreme case: $1.55 per milligram at DTC platforms versus $0.027 per milligram through Medicare — a 57-fold markup.
What the Evidence Shows Is Happening Inside DTC Care
Three studies, taken together, paint the picture.
Grant, de Silva, and Jayasena (JCEM 2026) analyzed testosterone-related online content across four languages (English, Arabic, Hindi, Spanish) and three search engines. Their findings: publicly accessible information from DTC providers is "frequently inaccurate, without consensus evidence base, and violates advertising laws." The 12-fold increase in global testosterone prescriptions over two decades occurred without any corresponding increase in hypogonadism prevalence. The growth is demand-driven, not disease-driven.
Dubin and colleagues (JAMA Internal Medicine, 2022) sent a secret shopper with verified normal testosterone levels to seven DTC platforms. Six of seven offered treatment. Only one asked about cardiovascular risk. Half failed to mention fertility risk despite the "patient" stating he wanted children. Guideline compliance: 14.3%.
Woloshin and Gill (JAMA Internal Medicine, 2023), in the editorial accompanying Dubin's findings, called the results "egregious" and "bad medical practice." They recommended that the Federation of State Medical Boards conduct undercover spot checks of randomly selected telehealth sites. No such program has been implemented.
"The online comments that the doctors don't know anything about [testosterone] are accurate."
— Abraham Morgentaler, MD, Harvard Medical School, quoted in STAT News, November 2025
This quote captures the trap. The access crisis and the information crisis feed each other. Patients go to DTC because mainstream medicine fails them. DTC fills the vacuum with a model optimized for revenue, not clinical rigor. The cycle reinforces itself.
The Clift Paradox
The irony deepens. The largest real-world testosterone outcome dataset of 2026 comes from a DTC clinic.
Clift and Morgentaler (World Journal of Men's Health, 2026) published outcomes from Menwell Ltd, a UK direct-to-consumer men's health provider: 9,537 men, median age 42, median BMI 28.21, mean follow-up 8.47 months. Baseline testosterone rose from 10.7 to 28.05 nmol/L at 12 months. All eight quality-of-life domains improved significantly.
But the details tell a more complicated story.
| Finding | Data | Implication |
|---|---|---|
| Combination therapy | 58.8% T+hCG, 75.2% any hCG use | Zero RCTs exist for T+hCG combination |
| Polycythemia | 24.15% hematocrit >0.54 | Threshold requiring clinical action |
| Follow-up duration | Mean 8.47 months | TRAVERSE: 33 months. Long-term safety unknown. |
| Formulation | 80.9% subcutaneous cypionate | TRAVERSE used gel. Different pharmacokinetics. |
| Safety events | Extracted from free-text notes | No structured adverse event coding |
| Age | Median 42 years | TRAVERSE: mean 63. Different population entirely. |
Three-quarters of the patients received hCG alongside testosterone — a combination my treatment framework identified as the most common real-world protocol and simultaneously the one with zero randomized controlled trial evidence. The evidence void map from that article shows the gap: the treatment most men actually receive has never been formally studied for safety or efficacy as a combination.
One in four patients developed polycythemia above the threshold requiring clinical action. The safety event data was extracted from free-text clinical notes rather than structured coding — meaning adverse events were captured only when someone happened to write them down.
Clift and Morgentaler's paper is not evidence of DTC failure. It's evidence that DTC can collect data at scale. But it's also evidence that the data being collected is not the data we need. And it confirms the central problem: real-world prescribing has outrun the evidence base.
What the Framework Reveals
My treatment decision framework — built across 28 deep dives into the mechanisms of secondary hypogonadism — identifies a five-layer treatment cascade:
The standard DTC model — symptoms questionnaire, blood test, prescription, monthly billing — begins at Layer 3. Layers 1 and 2 are erased. Layer 4 is invisible. Layer 5 doesn't exist.
This isn't a minor gap. A man whose testosterone is low because of obesity (the metabolic trap) and is prescribed injectable testosterone without addressing the five interlocking feedback loops will see his numbers rise on paper while the disease progresses underneath. A man whose testosterone is low because of antipsychotic medication (triple mechanism) needs a dose adjustment or medication switch, not a parallel hormone prescription that interacts with his existing treatment in unstudied ways. A man who wants children and is not warned about the fertility collision may discover irreversible damage months later.
The etiology question — why is this man's testosterone low? — is not academic. It determines which layer of the cascade to enter, which treatment modality to use, which paradoxes to monitor, and which evidence voids to acknowledge. No subscription model asks it.
The Regulatory Collision Course
Four forces are converging on a single deadline.
Force 1: The telehealth cliff. The Ryan Haight Act (2008) requires an in-person evaluation before prescribing controlled substances via telemedicine. Pandemic flexibilities have been extended four times. The current extension expires December 31, 2026. In 2024, 7 million of 44.6 million controlled substance prescriptions were written without a prior in-person visit. If the extension lapses without replacement legislation, the entire DTC testosterone infrastructure faces disruption overnight.
Force 2: The descheduling question. If testosterone is removed from Schedule III, the Ryan Haight Act becomes irrelevant for testosterone prescribing — telemedicine restrictions on controlled substances wouldn't apply. But descheduling requires Congressional action, and no bill has advanced. The DTC industry has strong incentives to lobby for descheduling not because of patient access, but because it would eliminate the single biggest regulatory threat to their business model.
Force 3: The oversight vacuum. California removed testosterone from its prescription monitoring program. No federal equivalent of Woloshin's proposed FSMB spot-check program exists. The Endocrine Society wants more data but has no enforcement mechanism. Public Citizen demands reinstatement of the black box warning but was overridden by the expert panel. The DTC industry operates in a space where the theoretical regulators disagree with each other about what the rules should be.
Force 4: The stakeholder deadlock.
The deadlock creates a predictable dynamic: the DTC industry moves fastest, the regulators move slowest, and the evidence base falls further behind both.
The Test
The question is not whether DTC testosterone clinics should exist. The access crisis is real, and mainstream medicine's failure to diagnose and treat hypogonadism created the vacuum that DTC fills. The question is what guideline-concordant DTC care would actually look like.
It would mean asking why before prescribing what. A man presenting with fatigue, low libido, and a testosterone of 250 ng/dL is not a subscription customer. He's a clinical puzzle. Is he on opioids? Does his BMI suggest the metabolic trap? Is he taking an SSRI or antipsychotic? Has he had a blast TBI? Does he want children? Has anyone checked his prolactin?
It would mean acknowledging the evidence voids. The most common real-world protocol (testosterone plus hCG) has never been tested in a randomized trial. Enclomiphene — now available through Hims as a compounded product — has no FDA approval and zero cardiovascular outcome data. The formulation most DTC clinics use (subcutaneous injectable cypionate) is not the formulation TRAVERSE studied (topical gel). Every patient in DTC care is being treated in evidence gaps, and none of them are told.
It would mean monitoring for the paradoxes. Testosterone improves bone density but may increase fractures. It suppresses autoimmunity but weakens antiviral defense. It raises the question of gonadotropin-mediated neurodegeneration that no one is studying in this context. An 8.47-month mean follow-up catches none of this.
And it would mean transparent pricing. A man paying $4,200 per year for injectable testosterone that costs $134 at a tertiary center deserves to know why.
The bottom line: Testosterone treatment should be easier to access. It should not be easier to access than the information needed to use it safely. Right now, it is.
Sources
Grant B, de Silva NL, et al. Discordance Between Online Information and Male Hypogonadism Clinical Guidelines: A Global Multilingual Content Analysis. JCEM 2026. doi:10.1210/clinem/dgaf689
Dubin JM, et al. Testosterone Replacement Therapy and Direct-to-Patient Platforms. JAMA Intern Med 2022;183(4):288. doi:10.1001/jamainternmed.2022.6009
Woloshin S, Gill L. Direct-to-Consumer Low-Testosterone Clinics—Where Is the Federation of State Medical Boards? JAMA Intern Med 2023;183(4):288-289. doi:10.1001/jamainternmed.2022.7008
Clift RA, Morgentaler A. Real-World Outcomes of Testosterone Therapy. World J Mens Health 2026. doi:10.5534/wjmh.240251
STAT News. Why men are flocking to dubious online clinics for testosterone therapy. November 21, 2025. statnews.com
KFF Health News/CBS. Testosterone therapy marketed to military veterans. March 21, 2024. kffhealthnews.org
Endocrine Society. Comments to FDA, Docket FDA-2025-N-6743. February 6, 2026. endocrine.org
Public Citizen. Comments on FDA Testosterone Expert Panel. February 2026. citizen.org
Bhasin S, et al. Testosterone Treatment in Men with Hypogonadism (TRAVERSE). NEJM 2023. doi:10.1056/NEJMoa2215025
Dubin JM, et al. Direct-to-Consumer Testosterone Pricing. J Sex Med 2022. doi:10.1093/jsxmed/qdac045